Kura Oncology, Inc.
Символ: KURA
NASDAQ
18.19
USDПазарна цена днес
-9.4057
Съотношение P/E
-0.2648
Коефициент PEG
1.38B
MRK Cap
- 0.00%
Доходност на DIV
Kura Oncology, Inc. (KURA) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1759.43 | 424 | 438 | 518 | ||||||||||||||||
balance-sheet.row.short-term-investments | 1617.19 | 386.6 | 386.2 | 427.3 | ||||||||||||||||
balance-sheet.row.net-receivables | 2.8 | 2.8 | 0 | 0 | ||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-current-assets | 32.27 | 5.7 | 8.4 | 4.3 | ||||||||||||||||
balance-sheet.row.total-current-assets | 1785.83 | 432.5 | 446.4 | 522.3 | ||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 29.14 | 8.9 | 6.4 | 8.2 | ||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.long-term-investments | 0.82 | 0.2 | 0.2 | 0.2 | ||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-non-current-assets | 18.97 | 7.4 | 3.3 | 3.3 | ||||||||||||||||
balance-sheet.row.total-non-current-assets | 48.92 | 16.5 | 9.9 | 11.8 | ||||||||||||||||
balance-sheet.row.other-assets | 8.67 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-assets | 1843.42 | 448.9 | 456.3 | 534.1 | ||||||||||||||||
balance-sheet.row.account-payables | 9.69 | 2.3 | 1.5 | 3.2 | ||||||||||||||||
balance-sheet.row.short-term-debt | 7.87 | 1.5 | 2.3 | 2.3 | ||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.long-term-debt-total | 46.98 | 9.3 | 11.7 | 4.6 | ||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||
balance-sheet.row.other-current-liab | 92.46 | 31.5 | 20.2 | 17 | ||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 55.43 | 16.4 | 12 | 5 | ||||||||||||||||
balance-sheet.row.other-liabilities | -23.9 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.capital-lease-obligations | 22.64 | 6.4 | 4.9 | 6.9 | ||||||||||||||||
balance-sheet.row.total-liab | 137.45 | 51.7 | 36 | 27.4 | ||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.common-stock | 0.03 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.retained-earnings | -2643.02 | -721.4 | -568.8 | -433 | ||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -15.92 | -1.3 | -8 | -1.8 | ||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 2243.2 | 1120 | 8 | 1.8 | ||||||||||||||||
balance-sheet.row.total-stockholders-equity | -415.72 | 397.3 | -568.8 | -433 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | -254.37 | 448.9 | -532.8 | -405.5 | ||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-equity | -415.72 | 397.3 | -568.8 | -433 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | -254.37 | - | - | - | ||||||||||||||||
Total Investments | 1617.39 | 386.8 | 386.2 | 427.3 | ||||||||||||||||
balance-sheet.row.total-debt | 61.21 | 17.2 | 14 | 6.9 | ||||||||||||||||
balance-sheet.row.net-debt | -81.03 | -20.1 | -37.8 | -83.8 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -152.63 | -152.6 | -135.8 | -130.5 | ||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.85 | 0.8 | 0.8 | 0.6 | ||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -19.5 | 0 | 4.6 | ||||||||||||||||
cash-flows.row.stock-based-compensation | 28.08 | 28.1 | 26.3 | 23.6 | ||||||||||||||||
cash-flows.row.change-in-working-capital | 7.82 | 7.8 | -3 | -3.2 | ||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.account-payables | 10.33 | 10.3 | -0.8 | -2.5 | ||||||||||||||||
cash-flows.row.other-working-capital | -2.51 | -2.5 | -2.2 | -0.7 | ||||||||||||||||
cash-flows.row.other-non-cash-items | -8.94 | 10.5 | 1.7 | 0.4 | ||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -124.82 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.17 | -0.2 | -0.6 | -1.1 | ||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -15.6 | 0 | 0.1 | ||||||||||||||||
cash-flows.row.purchases-of-investments | -409.82 | -409.8 | -270.7 | -445.7 | ||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 425.55 | 425.5 | 303.9 | 320 | ||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 15.6 | 0 | -0.1 | ||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 15.56 | 15.6 | 32.6 | -126.8 | ||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -9.4 | -7.3 | ||||||||||||||||
cash-flows.row.common-stock-issued | 94.78 | 94.8 | 24.7 | 4.4 | ||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.other-financing-activites | 94.88 | 94.8 | 23.3 | -0.6 | ||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 94.78 | 94.8 | 38.6 | -3.4 | ||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.net-change-in-cash | -14.69 | -14.5 | -38.9 | -234.8 | ||||||||||||||||
cash-flows.row.cash-at-end-of-period | 142.66 | 37.3 | 52 | 90.9 | ||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 157.35 | 51.8 | 90.9 | 325.7 | ||||||||||||||||
cash-flows.row.operating-cash-flow | -124.82 | -124.8 | -110.1 | -104.6 | ||||||||||||||||
cash-flows.row.capital-expenditure | -0.17 | -0.2 | -0.6 | -1.1 | ||||||||||||||||
cash-flows.row.free-cash-flow | -124.99 | -125 | -110.7 | -105.7 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1.27 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.cost-of-revenue | 0.85 | 0.8 | 0.8 | 0.6 | ||||||||||||||||
income-statement-row.row.gross-profit | 0.42 | -0.8 | -0.8 | -0.6 | ||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.research-development | 115.23 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-general-administrative | 50.57 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.21 | - | - | - | ||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 4 | 0.8 | ||||||||||||||||
income-statement-row.row.operating-expenses | 165.59 | 165 | 139.9 | 131.3 | ||||||||||||||||
income-statement-row.row.cost-and-expenses | 165.8 | 165.8 | 139.9 | 131.3 | ||||||||||||||||
income-statement-row.row.interest-income | 14.72 | 14.7 | 4.3 | 1.2 | ||||||||||||||||
income-statement-row.row.interest-expense | 0.78 | 1.5 | 0.2 | 0.4 | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.21 | - | - | - | ||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 13.38 | 13.2 | 4.8 | 1.4 | ||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 4 | 0.8 | ||||||||||||||||
income-statement-row.row.total-operating-expenses | 13.38 | 13.2 | 4.8 | 1.4 | ||||||||||||||||
income-statement-row.row.interest-expense | 0.78 | 1.5 | 0.2 | 0.4 | ||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0.85 | 0.8 | 0.8 | 0.6 | ||||||||||||||||
income-statement-row.row.ebitda-caps | -161.1 | - | - | - | ||||||||||||||||
income-statement-row.row.operating-income | -162.14 | -165.8 | -140.6 | -131.8 | ||||||||||||||||
income-statement-row.row.income-before-tax | -152.63 | -152.6 | -135.8 | -130.5 | ||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | 0.2 | -0.6 | ||||||||||||||||
income-statement-row.row.net-income | -149.56 | -152.6 | -136.1 | -129.9 |
Често задавани въпроси
Какво е Kura Oncology, Inc. (KURA) общи активи?
Kura Oncology, Inc. (KURA) общите активи са 448935000.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 1270000.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е -1.616.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е -1.616.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е -117.767.
Какъв е общият приход на предприятието?
Общият приход е -127.669.
Каква е Kura Oncology, Inc. (KURA) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е -152631000.000.
Какъв е общият дълг на фирмата?
Общият дълг е 17200000.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 164955000.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 37318000.000.